Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajiv Kumar

Showing results (791-800 of 1,071) with videos related to

Pageof 108
Sort By:
Plos One|February 22, 2007
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosisSelma Ugurel, Ranjit K Thirumaran, Sandra Bloethner, et al.
Ecancermedicalscience|August 3, 2022
Treatment pattern and outcomes in <i>de novo</i> T790M-mutated non-small cell lung cancerGoutam Santosh Panda, Vanita Noronha, Darshit Shah, et al.
Journal of Biochemical and Molecular Toxicology|April 16, 2021
Cardioprotective effects of azilsartan compared with that of telmisartan on an in vivo model of myocardial ischemia-reperfusion injuryShanky Garg, Sana Irfan Khan, Rajiv Kumar Malhotra, et al.
Science (New York, N.Y.)|January 26, 2013
TERT promoter mutations in familial and sporadic melanomaSusanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, et al.
Clinical Colorectal Cancer|December 31, 2013
Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumorRajiv Kumar, Timothy J Price, Carol Beeke, et al.
Medical Journal, Armed Forces India|November 20, 2023
Bone marrow transplant: A two-decade single centre hematology experienceRajiv Kumar, Rajan Kapoor, Sanjeevan Sharma, et al.
Oncotarget|January 23, 2016
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanomaChristoph Willmes, Rajiv Kumar, Jürgen C Becker, et al.
Chemmedchem|July 8, 2021
METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular ProcessesElena V Moroz-Omori, Danzhi Huang, Rajiv Kumar Bedi, et al.
Genes, Chromosomes & Cancer|September 12, 2018
Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma riskSivaramakrishna Rachakonda, Haiying Kong, Nalini Srinivas, et al.
Neuroradiology|September 13, 2017
New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastomaTunc F Ersoy, Vera C Keil, Dariusch R Hadizadeh, et al.
Pageof 108

Showing results (791-800 of 1,071) with videos related to

Sort By:
Pageof 108
Plos One|February 22, 2007
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosisSelma Ugurel, Ranjit K Thirumaran, Sandra Bloethner, et al.
Ecancermedicalscience|August 3, 2022
Treatment pattern and outcomes in <i>de novo</i> T790M-mutated non-small cell lung cancerGoutam Santosh Panda, Vanita Noronha, Darshit Shah, et al.
Journal of Biochemical and Molecular Toxicology|April 16, 2021
Cardioprotective effects of azilsartan compared with that of telmisartan on an in vivo model of myocardial ischemia-reperfusion injuryShanky Garg, Sana Irfan Khan, Rajiv Kumar Malhotra, et al.
Science (New York, N.Y.)|January 26, 2013
TERT promoter mutations in familial and sporadic melanomaSusanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, et al.
Clinical Colorectal Cancer|December 31, 2013
Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumorRajiv Kumar, Timothy J Price, Carol Beeke, et al.
Medical Journal, Armed Forces India|November 20, 2023
Bone marrow transplant: A two-decade single centre hematology experienceRajiv Kumar, Rajan Kapoor, Sanjeevan Sharma, et al.
Oncotarget|January 23, 2016
SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanomaChristoph Willmes, Rajiv Kumar, Jürgen C Becker, et al.
Chemmedchem|July 8, 2021
METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular ProcessesElena V Moroz-Omori, Danzhi Huang, Rajiv Kumar Bedi, et al.
Genes, Chromosomes & Cancer|September 12, 2018
Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma riskSivaramakrishna Rachakonda, Haiying Kong, Nalini Srinivas, et al.
Neuroradiology|September 13, 2017
New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastomaTunc F Ersoy, Vera C Keil, Dariusch R Hadizadeh, et al.
Pageof 108